Skip to content

Study · Observational study · n = 1,513 · 2020

10 results

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis.

Chang KC, Shao SC, Kuo S, Yang CY, Chen HY, Chan YY, Ou HT

Cardiovascular diabetology9 Oct 2020Cited by 16 (Europe PMC)

PMID33036617 (opens in a new tab)PMCIDPMC7547475 (opens in a new tab)DOI10.1186/s12933-020-01148-8 (opens in a new tab)PepBankPUB-33036617
Download PDFPubMedAsk about this study
Jump to 10 results

Summary

BackgroundHead-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide.MethodsWe conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019. Effectiveness outcomes were assessed at every 3 months in the 1-year follow-up. Propensity score techniques were applied to enhance between-group comparability. Significant differences in changes of effectiveness outcomes between treatment groups during the follow-up were examined and further analyzed using mixed-model repeated-measures approaches.ResultsA total of 1512 subjects receiving dulaglutide and 1513 subjects receiving liraglutide were identified. At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: - 1.06%, p < 0.001; liraglutide: - 0.83%, p < 0.001), with a significant between-group difference (- 0.23%, 95% confidence interval - 0.38 to - 0.08%, p < 0.01). Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline (dulaglutide: - 1.14 kg, - 3.08 U/L and - 2.08 mL/min/1.73 m2, p < 0.01; liraglutide: - 1.64 kg, - 3.65 U/L and - 2.33 mL/min/1.73 m2, p < 0.001), whereas only dulaglutide yielded a significant systolic blood pressure reduction (- 2.47 mmHg, p < 0.001). Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant.ConclusionsIn real-world T2D patients, dulaglutide versus liraglutide was associated with better glycemic control and comparable effects on changes of weight, blood pressure, and liver and renal functions.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, liraglutide lowered HbA1c significantly from baseline at 12 months.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, HbA1c fell after 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 12 months
    Study

    n = 1,513

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.83%
    liraglutide, 12 months

    Source sentences

    Summary
    At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: - 1.06%, p < 0.001; liraglutide: - 0.83%, p < 0.001), with a significant between-group difference (- 0.23%, 95% confidence interval - 0.38 to - 0.08%, p < 0.01).
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  2. 02HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, body weight declined significantly from baseline with liraglutide.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, body weight fell after 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at 12 months
    Study

    n = 1,513

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Weight change
    −1.64 kg
    liraglutide

    Source sentences

    Summary
    Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline
    2 context sentences
    Summary · context
    liraglutide: - 1.64 kg, - 3.65 U/L and - 2.33 mL/min/1.73 m2, p < 0.001
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  3. 03HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, alanine aminotransferase declined significantly from baseline with liraglutide.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, the liver enzyme ALT fell after 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseALT change at 12 months
    Study

    n = 1,513

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    ALT change
    −3.65 U/L
    liraglutide

    Source sentences

    Summary
    Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline
    2 context sentences
    Summary · context
    liraglutide: - 1.64 kg, - 3.65 U/L and - 2.33 mL/min/1.73 m2, p < 0.001
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  4. 04HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, estimated glomerular filtration rate declined significantly from baseline with liraglutide.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, a kidney function measure (eGFR) fell slightly after 12 months of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseeGFR change at 12 months
    Study

    n = 1,513

    Comparator
    Baseline
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    eGFR change
    −2.33 mL/min/1.73 m<sup>2</sup>
    liraglutide

    Source sentences

    Summary
    Both treatments yielded significant declines in weight, alanine aminotransferase level, and estimated glomerular filtration rate from baseline
    2 context sentences
    Summary · context
    liraglutide: - 1.64 kg, - 3.65 U/L and - 2.33 mL/min/1.73 m2, p < 0.001
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  5. 05HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, liraglutide did not produce a significant systolic blood pressure reduction, unlike dulaglutide.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, systolic blood pressure did not fall significantly with liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSystolic blood pressure change at 12 months
    Study

    n = 1,513

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    whereas only dulaglutide yielded a significant systolic blood pressure reduction (- 2.47 mmHg, p < 0.001
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  6. 06HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, HbA1c fell less with liraglutide than with dulaglutide at 12 months.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, HbA1c fell less with liraglutide than with dulaglutide.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c change, liraglutide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HbA1c between-group difference
    −0.23%
    dulaglutide versus liraglutide, 12 months

    Source sentences

    Summary
    At 12 months, significant HbA1c changes from baseline were found in both treatments (dulaglutide: - 1.06%, p < 0.001; liraglutide: - 0.83%, p < 0.001), with a significant between-group difference (- 0.23%, 95% confidence interval - 0.38 to - 0.08%, p < 0.01).
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  7. 07HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, the between-group difference in weight change at 12 months, liraglutide versus dulaglutide, was not significant.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, weight change with liraglutide did not differ significantly from dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeWeight change, liraglutide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant.
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  8. 08HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, the between-group difference in blood pressure change at 12 months, liraglutide versus dulaglutide, was not significant.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, blood pressure change with liraglutide did not differ significantly from dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeBlood pressure change, liraglutide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant.
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  9. 09HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, the between-group difference in liver function change at 12 months, liraglutide versus dulaglutide, was not significant.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, liver function change with liraglutide did not differ significantly from dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeLiver function change, liraglutide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant.
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.
  10. 10HumanObservational studyEfficacy outcome

    In real-world Asian adults with type 2 diabetes, the between-group difference in renal function change at 12 months, liraglutide versus dulaglutide, was not significant.

    In plain wordsIn real-world adults with type 2 diabetes in Taiwan, kidney function change with liraglutide did not differ significantly from dulaglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeRenal function change, liraglutide versus dulaglutide
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Between-group differences in changes of weight, blood pressure, and liver and renal functions at 12 months were not statistically significant.
    1 context sentence
    Summary · context
    We conducted a retrospective cohort study by utilizing multi-institutional electronic medical records to identify real-world type 2 diabetes patients treated with dulaglutide or liraglutide during 2016-2018 in Taiwan and followed up until 2019.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 11:11 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.